Peripheral Blood Eosinophils and Nine Years Mortality in COPD Patients

Figures & data

Figure 1 Cause of death according to 2004 GOLD severity classification at baseline.

Figure 2 Percentage of eosinophils in relation to total leukocytes.

Figure 3 Kaplan–Meier curve in relation to categorizing patients with eosinophils ≥2% (A) and ≥150 cells (B).

Table 1 Cox Regression Analysis to Evaluate the Association Between Percentage of Eosinophils <2% and Mortality Over Nine Years

Variables	Hazard Ratio (IC95%)	p value
Gender (male)	0.62 (0.78–3.38)	0.20
Age (years)	1.02 (0.98–1.07)	0.35
SpO2 (%)	0.92 (0.84–1.00)	0.06
FEV1, %	1.00 (0.99–1.02)	0.72
6MWT, meters	0.99 (0.99–0.99)	0.01
mMRC, score	1.07 (0.75–1.53)	0.70
Eosinophil: ≥2% (ref)
<2%	3.13 (1.38–7.07)	0.006

Abbreviations: SpO₂, pulse oximetry; FEV₁, forced expiratory volume in the first second; mMRC, Medical Research Council modified; 6MWT, distance walked in the six-minute walk test.

Table 2 Cox Regression Analysis to Evaluate the Association Between <150 Eosinophil Cells and Mortality Over Nine Years

Variables	Hazard Ratio (IC95%)	p value
Gender (male)	1.86 (0.83–4.17)	0.13
Age (years)	1.03 (1.00–1.10)	0.03
SpO2 (%)	0.90 (0.83–0.98)	0.01
FEV1, %	1.00 (0.99–1.02)	0.80
6MWT, meters	0.99 (0.99–1.00)	0.10
mMRC, score	1.09 (0.73–1.61)	0.68
Eosinophil: ≥150 cells (ref)
<150	3.02 (1.42–6.42)	0.004

Abbreviations: SpO₂, pulse oximetry; FEV₁, forced expiratory volume in the first second; mMRC, Medical Research Council modified; 6MWT, distance walked in the six-minute walk test.